Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
Ashwani Gujral of ashwanigujral.com is of the view that one can buy Colgate Palmolive and Godrej Consumer and sell Dr Reddy's Labs and Lupin.
Regulatory woes continue for Biocon. The United States Foods and Drug Administration (USFDA) issued a form 483 with 10 observations to the Bangalore plant.
In an interview to CNBC-TV18, Surajit Pal of Prabhudas Lilladher shared his views and readings on two stocks from pharma space - Glenmark Pharma and Biocon.
Sudarshan Sukhani of s2analytics.com is of the view that one may buy Vedanta, Reliance Industries, Motherson Sumi and Ceat and sell SRF.
Ashwani Gujral of ashwanigujral.com suggests buying ICICI Prudential, Reliance Capital and Mahanagar Gas.
Ashwani Gujral of ashwanigujral.com is of the view that one can buy Voltas, Gruh Finance and IGL and can sell Punjab National Bank and Delta Corp.
Vijay Chopra of enochventures.com is of the view that one may hold Biocon.
Rajat Bose of rajatkbose.com feels that Biocon may test Rs 491.
Ashish Kyal of Waves Strategy Advisors is of the view that one may buy Biocon with a target of Rs 418.
Sudarshan Sukhani of s2analytics.com is of the view that one can sell Havells India and Kwality and buy Hindustan Unilever and Biocon while can hold Indo Count Industries.
Ashwani Gujral of ashwanigujral.com recommends buying Dewan Housing Finance, HDFC Bank and Bajaj Finserv.
Ashwani Gujral of ashwanigujral.com is of the view that one can buy Britannia Industries and sell UltraTech Cement and Jubilant Foodworks.
Ashwani Gujral of ashwanigujral.com suggests buying Century Plyboards, Brigade Enterprises, HUDCO, Aurobindo Pharma and Biocon.
Ashwani Gujral of ashwanigujral.com recommends buying Ashok Leyland, Biocon and Dewan Housing Finance.
In an interview to CNBC-TV18's Anuj Singhal and Surabhi Upadhyay, SP Tulsian of sptulsian.com shared his views and outlook on the fundamentals of the market and specific stocks.
The United States Foods and Drug Administration (USFDA) Oncologic Drugs Advisory Committee (ODAC) has recommended an approval of a biosimilar trastuzumab in the US. Trastuzumab is Biocon and Mylan's biosimilar which is a biosimilar version of Herceptin used to treat breast cancer in the US market. Watch accompanying video of Vishal Manchanda of Nirmal Bang Institutional Equities in which he shared his readings and views on the same.
Ashwani Gujral of ashwanigujral.com is of the view that one can buy Biocon and Aurobindo Pharma on every dip and advises selling Axis Bank and Adani Ports.
The committee will discuss biosimilarity of the product and label extrapolation application by Mylan/Biocon given that they have conducted clinical trials on only one of the three indications, said CLSA.
Ashwani Gujral of ashwanigujral.com recommends buying ICICI Bank, Interglobe Aviation, Gruh Finance, Uflex and Equitas Holdings.
In an interview to CNBC-TV18's Anuj Singhal and Varinder Bansal, SP Tulsian of sptulsian.com shared his views and outlook on the fundamentals of the market and specific stocks.
Ashwani Gujral of ashwanigujral.com is of the view that one may buy Sintex Industries, Biocon, HPCL and Bharti Infratel.
Mitessh Thakkar of mitesshthakkar.com is of the view that one may buy IGL, NTPC and Hexaware Technologies and can sell HDIL.
If approved by the regulator, it will be the first Herceptin biosimilar in the US market, a development largely seen as positive for the company.
Say the development could be an overhang on the stock, but also bet on the company being a beneficiary of global biosimilar opportunity.
Lupin, Reliance Industries, and Biocon, among others are being tracked by analysts on Tuesday.